Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Author's Contribution

The author read and approved the final manuscript.

Funding

None.

Conflict of Interest

None declared.

References

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2020. CA Cancer J Clin 2020; 70(01): 7-30

[2] Feng RM, Zong YN, Cao SM, Xu RH.Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Commun (Lond) 2019; 39(01): 22

[3] Cao M, Li H, Sun D, Chen W.Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020; 40(05): 205-210

[4] André F, Ciruelos E, Rubovszky G.et al; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019; 380(20): 1929-1940

[5] Ding S, Chen X, Shen K.Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun (Lond) 2020; 40(08): 329-344

[6] Rugo HS, Rumble RB, Macrae E.et al.Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34(25): 3069-3103

[7] Guan X, Ma F, Li C.et al.The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun (Lond) 2019; 39(01): 1

[8] Slamon DJ, Neven P, Chia S.et al.Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018; 36(24): 2465-2472

[9] Harbeck N, Iyer S, Turner N.et al.Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 2016; 27(06): 1047-1054

[10] Sobhani N, Roviello G, Corona SP.et al.The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem 2018; 119(06): 4287-4292

[11] Baselga J, Im SA, Iwata H.et al.Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18(07): 904-916

[12] André F, Ciruelos EM, Juric D.et al.Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021; 32(02): 208-217

[13] Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002; 7(Suppl. 06): 13-19

[14] Didwaniya N, Tanco K, de la Cruz M, Bruera E. The need for a multidisciplinary approach to pain management in advanced cancer: a clinical case. Palliat Support Care 2015; 13(02): 389-394

[15] Ciruelos EM, Rugo HS, Mayer IA.et al.Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1. J Clin Oncol 2021; 39(18): 2005-2015

RIGHTS & PERMISSIONS

Global Medical Genetics